Article: NO EVIDENCE OF CARDIOVASCULAR SAFETY SIGNAL FOR PFIZER'S CELEBREX.

(Full text of a statement, contact details below)

NEW YORK, Oct. 1 /PRNewswire-FirstCall-AsiaNet/ -- Pfizer Inc said today that three large long-term Celebrex (celecoxib capsules) studies involving more than 6,000 patients have not shown any significant safety issues and are expected to continue to completion.

The ongoing studies, which are assessing Celebrex as a potential preventative treatment in both Alzheimer's disease and colorectal cancer, have been under way at multiple medical centers worldwide for several years. The studies are being conducted by the National Cancer Institute, the National Institutes of Health and Pfizer.

The evidence ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!